MENU
ATEC
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

ATEC stock forecast, quote, news & analysis

Alphatec Holdings Inc is a medical technology company focused on the designing, development, and advancement of products for the surgical treatment of spinal disorders associated with disease and degeneration, congenital deformities, and trauma... Show more

Interact to see
Advertisement
A.I.Advisor
published price charts
A.I.Advisor
Nov 13, 2026

Why Alphatec Holdings (ATEC) Stock Is Down -32% in the Last 30 Days

Key Takeaways

  • Alphatec Holdings (ATEC) shares have declined roughly 32% over the last 30 days, with most of the loss concentrated in a single session following its third-quarter earnings report.
  • The stock fell about 38% on October 30, 2026, after Q3 revenue of $221.2 million missed estimates and management cut full-year revenue guidance.
  • Full-year 2026 revenue guidance was lowered to approximately $862 million from roughly $882 million, citing lower biologics attachment rates, softer thoracolumbar volumes, EOS installation timing, and a temporary international supply constraint.
  • Underlying operations stayed resilient, with case volumes up about 20%, new surgeon growth near 25%, and adjusted EBITDA margin expanding to roughly 17.3%.
  • Several sell-side analysts trimmed price targets while maintaining Buy ratings, and multiple law firms announced shareholder investigations following the guidance cut.
  • For deeper data, review ATEC's Price Targets, Earnings, and Forecast pages.
  • Discover automated trading strategies on the Trending AI Robots page.

Alphatec Holdings (ATEC) Company Overview and Market Position

Alphatec Holdings, Inc. is a medical device company focused on the surgical treatment of spine disorders. Through its subsidiaries Alphatec Spine, EOS imaging, and SafeOp Surgical, the company develops implants, fixation systems, access systems, biologics, patient positioning technology, and intraoperative navigation. Its InformatiX platform integrates the EOS imaging system, the EOS Insight surgical planning software, the SafeOp Neural InformatiX monitoring system, and the Valence navigation-enabled robotics platform.

Alphatec differentiates itself by selling complete procedural solutions rather than individual products, with a particular strength in lateral spine surgery. Investors follow the stock closely because of its rapid revenue growth, expanding surgeon adoption, and progress toward sustained profitability in a spine market that includes competitors such as Globus Medical and Medtronic.

Alphatec Holdings (ATEC) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, ATEC shares have fallen roughly 32%, declining from a close near $10.44 in mid-October to around $7.12 in recent trading. The move was abrupt rather than gradual: the stock traded near $11.37 on October 29, then plunged about 38% in a single session the following day — its worst one-day decline in more than a decade.

The quarterly picture tells a similar story. About three months earlier, the stock closed near $9.79, meaning ATEC has shed approximately 27% over the last quarter. Notably, the shares actually rallied through much of the period — climbing from the low $8.80s in early September to an intraday high above $12 in late October — before the post-earnings selloff erased those gains and pushed the stock to multi-month lows.

What Drove ATEC Stock Price in the Last 30 Days

The primary catalyst was the company's third-quarter 2026 earnings report, released after the market close on October 29. Total revenue grew 13% year over year to $221.2 million, but fell short of the roughly $225 million analysts had expected, and adjusted earnings per share of $0.09 came in below consensus. The shortfall was driven largely by lower biologics attachment — the bone-graft products sold alongside implants — as well as softer thoracolumbar procedure volumes.

Management also reduced full-year 2026 revenue guidance to approximately $862 million, down from the roughly $882 million it had reaffirmed in August, and trimmed free cash flow expectations. The guidance cut marked the second reduction of the year and raised questions about the company's ability to convert strong procedure growth into revenue per case. The market's reaction was amplified by the fact that the miss landed on biologics, the most variable part of Alphatec's growth model, and by broader sector weakness. In the following days, several analysts lowered price targets, and multiple law firms announced shareholder investigations into the company's prior statements.

What Drove ATEC Stock Performance Over the Last Quarter

Across the last three months, the dominant narrative has been a shift from steady accumulation toward a sharp repricing of growth expectations. Through September and most of October, the stock climbed as investors weighed Alphatec's strong procedural momentum — double-digit case-volume growth, record new surgeon additions, and improving margins — against concerns about execution in biologics and EOS capital placements.

The October earnings release crystallized those concerns. While adjusted EBITDA rose 46% to $38.3 million and gross margin improved nearly 200 basis points to about 72%, the revenue miss and guidance cut signaled that procedure growth was not translating into revenue-per-case expansion as expected. The combination of a second guidance reduction in six months, a thinner cash balance of about $80 million, and management's cautious tone on biologics recovery reset investor sentiment and compressed the stock's valuation multiple, leaving the shares sharply lower for the quarter despite the earlier rally.

Trending AI Robots

Tickeron operates a marketplace of hundreds of AI-driven trading bots that collectively monitor thousands of tickers. Rather than displaying every strategy, the Trending AI Robots page curates only the top-performing and most relevant bots, making it easier for users to identify strategies gaining traction in current market conditions. These bots span a range of approaches, timeframes, and performance metrics, from short-term momentum models to longer-horizon trend-following systems, so investors can compare methodologies and select tools aligned with their own objectives. For those looking to supplement fundamental research with data-driven automation, the Trending AI Robots page offers a practical starting point.

ATEC Stock Forecast Drivers: What Investors Should Watch Next

The next major checkpoint is the company's fourth-quarter and full-year report, which will reveal whether biologics attachment recovered and whether the guidance reset proved conservative. Investors should monitor revenue per case, biologics contribution, thoracolumbar procedure trends, and EOS installation activity, alongside progress on the Valence robotics rollout and EOS Insight adoption. Competitive commentary from spine peers, macroeconomic pressure on elective procedure volumes, and any developments from the announced shareholder investigations may also influence sentiment. Management has indicated it is still finalizing its 2027 plan, so any forward commentary on growth and profitability targets will be closely watched.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

A.I.Advisor
a Summary for ATEC with price predictions
Nov 20, 2026

ATEC in downward trend: 10-day moving average crossed below 50-day moving average on November 03, 2026

The 10-day moving average for ATEC crossed bearishly below the 50-day moving average on November 03, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ATEC as a result. In 65 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 70%.

The Moving Average Convergence Divergence Histogram (MACD) for ATEC turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 31 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 74%.

ATEC moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ATEC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ATEC's RSI Oscillator exited the oversold zone, 28 of 36 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 14 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +4.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where ATEC advanced for three days, in 268 of 319 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

ATEC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 217 of 253 cases where ATEC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 86%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 33 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 83 (best 1 - 100 worst), indicating slightly worse than average price growth. ATEC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ATEC's P/B Ratio (-95.212) is very low in comparison to the industry average of (4.142). P/E Ratio (-10.479) is within average values for comparable stocks, (3.291). ATEC's Projected Growth (PEG Ratio) (91.200) is very high in comparison to the industry average of (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (1.980) is also within normal values, averaging (40.124).

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ATEC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -11%. For the same Industry, the average monthly price growth was -15%, and the average quarterly price growth was -18%. MXCT experienced the highest price growth at 15%, while CODX experienced the biggest fall at -50%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was -36%. For the same stocks of the Industry, the average monthly volume growth was -3% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 49
Price Growth Rating: 64
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 16 (-100 ... +100)
View a ticker or compare two or three
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a holding company with interests in medical equipment and supplies

Industry MedicalNursingServices

Industry
Medical Specialties
Address
1950 Camino Vida Roble
Phone
+1 760 431-9286
Employees
913
Web
https://www.atecspine.com
Why Alphatec Holdings (ATEC) Stock Is Down -32% in the Last 30 Days